NOV 17, 202658 MINS READ
Croscarmellose Sodium is synthesized through intramolecular cross-linking of sodium carboxymethylcellulose (NaCMC) with a degree of substitution (DS) typically ranging from 0.60 to 0.85 8. The cross-linking reaction, catalyzed by sulfuric acid in aqueous organic solvents (e.g., ethanol-water mixtures at volume ratios of 10:1), proceeds in two stages: initial activation at 40–50°C for 0.5–2.0 hours, followed by cross-linking at 65–75°C for 2.0–4.0 hours 8. This controlled process yields a three-dimensional polymer network with carboxymethyl ether groups (-OCH₂COONa) distributed along the cellulose backbone, creating hydrophilic sites that drive rapid water absorption.
The resulting CCS exhibits a particle size distribution optimized for tableting, with commercial grades (e.g., Ac-Di-Sol®) typically ranging from 30 to 300 μm 13. Key physicochemical parameters include:
The cross-linked structure prevents dissolution while enabling rapid volumetric expansion upon contact with aqueous media. When incorporated into tablets at 1–10% (w/w) 6, CCS particles swell to 4–8 times their original volume within seconds, generating localized disruptive forces that fragment the tablet matrix through a combination of swelling pressure (estimated at 0.5–2.0 MPa based on confined swelling studies) and wicking action along capillary channels.
The superdisintegrant efficacy of Croscarmellose Sodium derives from three synergistic mechanisms that operate on sub-minute timescales in physiological fluids:
Upon immersion in dissolution media (e.g., 0.02N HCl at 37°C, simulating gastric conditions), CCS particles absorb water at rates exceeding 200% (w/w) within the first 10 seconds 10. This rapid hydration is driven by the osmotic gradient established by ionized carboxylate groups (-COO⁻Na⁺), which attract water molecules into the polymer network. The swelling kinetics follow a pseudo-first-order model, with half-maximal swelling (t₅₀) typically achieved in 5–15 seconds depending on particle size and compression force.
The fibrous morphology of CCS creates an extensive network of micro-channels (1–10 μm diameter) within the tablet matrix. These channels facilitate rapid penetration of dissolution medium into the tablet core via capillary action, described by the Washburn equation: L = (γrcosθt / 2η)^(1/2), where L is penetration depth, γ is surface tension, r is capillary radius, θ is contact angle, and η is viscosity. For CCS-containing tablets, contact angles typically range from 20° to 40°, indicating strong hydrophilicity and efficient wicking 2.
As CCS particles expand, they exert radial pressure on surrounding excipients and API particles, mechanically disrupting inter-particulate bonds formed during compression. Finite element modeling suggests localized stress concentrations of 1–3 MPa at CCS-excipient interfaces, sufficient to overcome typical tablet tensile strengths (0.5–2.0 MPa). This mechanism is particularly effective when CCS is distributed both intragranularly and extragranularly, creating a dual-phase disintegration system 4.
Quantitative Performance Data:
Optimizing CCS incorporation requires careful consideration of concentration, distribution strategy, and interactions with co-excipients to balance disintegration speed, mechanical strength, and manufacturing processability.
The optimal CCS concentration typically ranges from 2% to 8% (w/w) of the total tablet weight 2, 6, 13, with higher levels (up to 10%) employed for challenging formulations containing high-dose APIs or hydrophobic actives 9. Exceeding 10% CCS can compromise tablet hardness (reducing from 17–21 SCU to <12 SCU) and increase friability (>1.0%), while levels below 2% yield insufficient disintegration rates (>60 seconds) 3.
Dual-Phase Distribution Strategy:
Distributing CCS between intragranular (within granules) and extragranular (outside granules) phases enhances disintegration efficiency through complementary mechanisms 4, 6:
A 50:50 intragranular:extragranular distribution achieves disintegration times of ~20 seconds, whereas 25:75 or 75:25 ratios result in times exceeding 40 seconds 13. This phenomenon reflects the need for simultaneous surface and core disintegration to prevent formation of a hydrated gel layer that impedes water penetration.
Microcrystalline Cellulose (MCC): Co-processing CCS with MCC (10–50% w/w) provides compressibility and structural integrity while maintaining rapid disintegration 2, 4. The optimal MCC grade is Avicel PH-101 (50 μm mean particle size), which forms a porous matrix that accommodates CCS swelling without excessive hardness increase.
Mannitol: In orodispersible formulations, mannitol (55–70% w/w, particle size 30–300 μm) serves as a rapidly dissolving diluent with pleasant mouthfeel 13. Its crystalline structure provides adequate hardness (15–20 SCU) while dissolving quickly to expose CCS particles.
Sodium Lauryl Sulfate (SLS): Adding 50–100% (w/w) SLS relative to CCS content (e.g., 0.5–1.0% SLS with 1% CCS) mitigates disintegration time prolongation during accelerated stability testing (40°C/75% RH) 3. SLS reduces interfacial tension, enhancing water penetration and preventing age-related hardening.
Alginate Complexes: Co-processed additives containing 75–95% MCC and 5–25% calcium-sodium alginate complex (10–50% w/w of formulation) improve suspendibility in water, critical for pediatric and geriatric suspension tablets 2, 4.
Wet Granulation with CCS Slurry:
A preferred method involves preparing a 2–15% (w/w) CCS aqueous slurry and using it as the granulating fluid for the API and primary excipients 4. Key parameters include:
Direct Compression:
For moisture-sensitive APIs, CCS can be blended directly with other excipients. This approach requires:
Croscarmellose Sodium is the disintegrant of choice for ODTs designed to disintegrate in <30 seconds without water 5, 6, 13. In domperidone ODTs (10 mg dose), a formulation containing 7% CCS, 60% mannitol (160 μm), 2% maltodextrin, and 15% MCC achieves 20-second disintegration with acceptable hardness (12–15 SCU) and friability (<0.8%) 13. The maltodextrin acts as a dry binder, reducing the need for wet granulation and associated moisture exposure.
Taste Masking Integration:
CCS can simultaneously serve as a disintegrant and taste-masking agent when applied as a coating via fluidized bed processing 5, 6. Acetaminophen particles coated with 5–10% CCS (relative to drug weight) using a top-spray configuration (inlet air 60–70°C, spray rate 5–10 g/min) exhibit:
Suspension tablets disintegrate within seconds in water to form homogeneous suspensions containing precise API doses, ideal for patients with swallowing difficulties 2, 4. A representative formulation comprises:
These tablets achieve complete disintegration in <10 seconds when added to 50–100 mL water, forming suspensions stable for ≥5 minutes (sedimentation rate <2 mm/min) 2.
Paradoxically, CCS can be incorporated into sustained-release systems when combined with pH-modifying agents and hydrophobic polymers 11, 12. In formulations containing:
The CCS initially swells to create porous channels, but the hydrophobic polymer and alkaline salts modulate water ingress, achieving controlled release over 8–12 hours while maintaining structural integrity against gastrointestinal peristalsis 11, 12. This approach is particularly effective for drugs requiring sustained plasma levels, such as analgesics and antihypertensives.
For tablets containing ≥500 mg API or BCS Class II/IV compounds, CCS concentrations of 5–10% (w/w) combined with surfactants enhance dissolution 9. In triphenyl calcilytic tablets (for autosomal dominant hypocalcemia), a formulation with:
achieves ≥80% dissolution of the lipophilic API within 30 minutes in pH 6.8 phosphate buffer, compared to <40% for formulations with 5% CCS and no surfactant 9. The surfactant reduces interfacial tension (from ~50 mN/m to ~35 mN/m), facilitating CCS-mediated wetting and dispersion of hydrophobic drug particles.
Accurate quantification of CCS in finished tablets is essential for quality control, particularly in generic formulations where excipient levels must match reference products.
A validated method employs electrospray HPLC-CAD to detect CCS in complex matrices such as amonavir tablets 1. The procedure involves:
Sample Preparation:
Chromatographic Conditions:
Performance Metrics:
This method is particularly advantageous as CAD
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| FMC CORPORATION | Immediate-release tablets, orodispersible tablets (ODTs), and suspension tablets requiring rapid disintegration for pediatric and geriatric populations with swallowing difficulties. | Ac-Di-Sol | Enables rapid tablet disintegration within 20 seconds in oral cavity conditions and achieves ≥65% API dissolution within 10 minutes through dual-phase distribution strategy combining swelling pressure and capillary wicking mechanisms. |
| FMC CORPORATION | Orodispersible formulations of bitter-tasting APIs such as acetaminophen requiring immediate palatability and rapid onset of action without water. | Ac-Di-Sol Taste Masking System | Provides dual functionality as both taste-masking coating (70-85% panelist acceptance) and disintegrant when applied at 5-10% coating level via fluidized bed processing, maintaining tablet disintegration in 25-35 seconds. |
| AMERICAN HOME PRODUCTS CORPORATION | High-dose calcium supplement tablets (≥80% tricalcium phosphate) requiring long-term storage stability and consistent disintegration performance in resource-limited distribution environments. | Calcium Supplement Tablets | Incorporation of 50-100% sodium lauryl sulfate relative to croscarmellose sodium content prevents disintegration time prolongation during accelerated stability testing (40°C/75% RH) while maintaining tablet hardness of 17-21 SCU. |
| Shionogi & Co. Ltd. | Sustained-release tablets for analgesics and antihypertensives requiring prolonged plasma levels with structural integrity against mechanical stress in the GI tract. | Extended Release Formulation System | Combines 3-20% croscarmellose sodium with sodium/potassium carbonate (1-20%) and hydrophobic polymers (ethyl cellulose/HPMC) to achieve controlled 8-12 hour drug release while creating porous channels and withstanding gastrointestinal peristalsis. |
| CALCILYTIX THERAPEUTICS INC. | High-dose tablets (≥500 mg) and poorly soluble API formulations for autosomal dominant hypocalcemia treatment requiring enhanced bioavailability of hydrophobic therapeutic compounds. | Triphenyl Calcilytic Tablets | Utilizes 15-25% total croscarmellose sodium (10% intragranular + 10% extragranular) with surfactants (1-3%) to achieve ≥80% dissolution of lipophilic API within 30 minutes for BCS Class II compounds, compared to <40% with conventional formulations. |